openPR Logo
Press release

Lawsuit filed for Investors in shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)

11-10-2020 08:26 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) shares.

A lawsuit was filed on behalf of investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) shares.

An investor, who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), filed a lawsuit over alleged violations of Federal Securities Laws by Intercept Pharmaceuticals, Inc.

Investors who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) have certain options and for certain investors are short and strict deadlines running. Deadline: January 4, 2021. NASDAQ: ICPT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

New York based Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Intercept Pharmaceuticals, Inc’s lead product candidate is Ocaliva (obeticholic acid (“OCA”)), a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (“PBC”), a rare and chronic liver disease, in combination with ursodeoxycholic acid in adults. The Company is also developing OCA for various other indications, including nonalcoholic steatohepatitis (“NASH”).

In 2016, the U.S. Food and Drug Administration (“FDA”) granted accelerated approval of Ocaliva for treating PBC.
Then, in late 2017, both Intercept and the FDA issued warnings concerning the risk of overdosing patients with the drug, and multiple reports of severe liver injuries and deaths linked with its use.

Intercept Pharmaceuticals, Inc. reported that its annual Total Revenue rose from $179.8 million in 2018 to $252.00 million in 2019 and that its normalized Loss increased from $309.24 million in 2019 to $344.68 million in 2019.

On May 22, 2020, Intercept Pharmaceuticals, Inc. reported that the FDA “has notified Intercept that its tentatively scheduled June 9, 2020 advisory committee meeting (AdCom) relating to the company’s [NDA] for [OCA] for the treatment of liver fibrosis due to [NASH] has been postponed” to “accommodate the review of additional data requested by the FDA that the company intends to submit within the next week.”

On June 29, 2020, Intercept Pharmaceuticals, Inc. announced that the FDA had issued a Complete Response Letter (“CRL”) rejecting the Company’s NDA for Ocaliva for the treatment of liver fibrosis due to NASH. According to that press release, “[t]he CRL indicated that, based on the data the FDA has reviewed to date,” the FDA “has determined that the predicted benefit of OCA based on a surrogate histopathologic endpoint remains uncertain and does not sufficiently outweigh the potential risks to support accelerated approval for the treatment of patients with liver fibrosis due to NASH.” Intercept Pharmaceuticals, Inc. further advised, among other things, that the “[t]he FDA recommends that Intercept submit additional post-interim analysis efficacy and safety data from the ongoing REGENERATE study in support of potential accelerated approval and that the long-term outcomes phase of the study should continue.”

On October 8, 2020, news outlets reported that Intercept Pharmaceuticals, Inc. was “facing an investigation from the U.S. Food and Drug Administration over the potential risk of liver injury in patients taking Ocaliva, [Intercept’s] treatment for primary biliary cholangitis, a rare, chronic liver disease.”

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) declined from $125.00 per share in late 2019 to as low as $27.83 per share on October 23, 2020.

The plaintiff claims that between September 28, 2019 and October 7, 2020, the Defendants made false and/or misleading statements and/or failed to disclose that the Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s use in treating PBC, that the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales, that any purported benefits associated with OCA’s efficacy in treating NASH were outweighed by the risks of its use, that as a result, the FDA was unlikely to approve the Company’s NDA for OCA in treating patients with liver fibrosis due to NASH, and that as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) here

News-ID: 2185023 • Views: 377

More Releases from Shareholders Foundation

Lawsuit filed for Investors in shares of Franklin Wireless Corp. (NASDAQ: FKWL)
An investor, who purchased shares of Franklin Wireless Corp. (NASDAQ: FKWL), filed a lawsuit a over alleged violations of Federal Securities Laws by Franklin Wireless Corp. Investors who purchased shares of Franklin Wireless Corp. (NASDAQ: FKWL) have certain options and for certain investors are short and strict deadlines running. Deadline: June 15, 2021. NASDAQ: FKWL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. San Diego, CA
Investigation announced for Long-Term investors in shares NYSE: GTT over potenti …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of GTT Communications Inc. Investors who are current long term investors in GTT Communications Inc (NYSE: GTT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: GTT stocks follows a lawsuit filed against GTT
Investigation announced for Long-Term Investors in shares of CNB Financial Corpo …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at CNB Financial Corporation. Investors who purchased shares of CNB Financial Corporation (NASDAQ: CCNE) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain CNB Financial directors breached their fiduciary duties and caused damage to the company and its shareholders. Clearfield, PA
Investor Notice: Lawsuit for Investors in Infinity Q Diversified Alpha Fund Inve …
An investor in Infinity Q Diversified Alpha Fund Investor Class (NASDAQ: IQDAX) and Infinity Q Diversified Alpha Fund Institutional Class (NASDAQ: IQDNX), filed a lawsuit over alleged violations of Securities Laws in connection with certain allegedly false and misleading statements made between December 31, 2018 through February 22, 2021. Investors in Infinity Q Diversified Alpha Fund Investor Class (NASDAQ: IQDAX) and/or Infinity Q Diversified Alpha Fund Institutional Class (NASDAQ: IQDNX)

All 5 Releases


More Releases for Intercept

Investigation announced for Investors in shares of Intercept Pharmaceuticals, In …
An investigation was announced over potential securities laws violations by Intercept Pharmaceuticals, Inc. in connection with certain financial statements. Investors who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Intercept Pharmaceuticals, Inc. regarding its business, its prospects and its operations were
Primary Biliary Cholangitis (PBC) Treatment Market| 2017-2027 Key Players Interc …
Primary biliary cholangitis is also referred as primary biliary cirrhosis, is an autoimmune disease of liver that manifest into progressive cholestasis and lead to end-stage liver disease. Primary biliary cholangitis characterized by destruction of bile duct which transport the bile acid. Primary biliary cholangitis is detected in the late stage of disease. Primary biliary cirrhosis majorly seen in women’s in fourth or sixth decades of life. Primary biliary cholangitis generally
Global Fatty Liver Disease Drug Market 2017 : Intercept Pharmaceuticals, Allerga …
Fatty Liver Disease Drug Market 2017 A market study based on the " Fatty Liver Disease Drug Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Fatty Liver Disease Drug Market 2017’. The research report analyses the historical as well as present performance of the worldwide Fatty Liver Disease Drug industry, and makes predictions on the future status of Fatty Liver Disease Drug market
Global Alcoholic Hepatitis Drugs Market 2016- Verlyx Pharma Inc., Promethera Bio …
Market.Biz has recently launched new Market Research Report on "Alcoholic Hepatitis Drugs Market" is a in-depth and professional survey on Alcoholic Hepatitis Drugs Market. The research study Global Alcoholic Hepatitis Drugs Industry offers strategic assessment of the Global Alcoholic Hepatitis Drugs market. The industry report focuses on the growth opportunities, which will help the Global Alcoholic Hepatitis Drugs industry to expand operations in the existing markets. Major Manufacturers Analysis of Alcoholic